These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 20171417

  • 1. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
    Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ.
    Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
    [Abstract] [Full Text] [Related]

  • 2. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, Burger H.
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [Abstract] [Full Text] [Related]

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 4. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [Abstract] [Full Text] [Related]

  • 6. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [Abstract] [Full Text] [Related]

  • 7. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [Abstract] [Full Text] [Related]

  • 8. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [Abstract] [Full Text] [Related]

  • 9. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
    Lloyd K, Latif MA, Simpson S, Shrestha KL.
    Hum Psychopharmacol; 2010 Apr; 25(3):243-52. PubMed ID: 20373476
    [Abstract] [Full Text] [Related]

  • 12. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M, Diekamp B, Gerwe M, Schreiner A, Ibach B.
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [Abstract] [Full Text] [Related]

  • 13. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
    Se Hyun Kim, Dong Chung Jung, Yong Min Ahn, Yong Sik Kim.
    J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641
    [Abstract] [Full Text] [Related]

  • 14. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J, San Molina L, Rubio G, Rodriguez-Morales A, Hidalgo Borrajo R, Burón JA.
    Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L.
    Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
    [Abstract] [Full Text] [Related]

  • 16. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P, Bret MC, Queuille E.
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
    Lammers L, Zehm B, Williams R.
    BMC Psychiatry; 2013 May 30; 13():155. PubMed ID: 23718192
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.